Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Debt / NOTE 0.625% 4/0
-
Number of holders
-
45
-
Total 13F principal, excl. options
-
415,075,000
-
Principal change
-
+10,314,935
-
Total reported value, excl. options
-
$408,576,605
-
Value change
-
+$10,082,645
-
Number of buys
-
11
-
Number of sells
-
-6
-
Price
-
$0.9825
Significant Holders of SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q4 2022
47 filings reported holding 868459AD0 - SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q4 2022.
SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 has 45 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $415,075,000 of principal
.
Largest 10 bondholders include TENOR CAPITAL MANAGEMENT Co., L.P. ($96,994,000 of principal), Radcliffe Capital Management, L.P. ($69,010,000 of principal), Opti Capital Management, LP ($46,902,000 of principal), DeepCurrents Investment Group LLC ($41,092,000 of principal), OAKTREE CAPITAL MANAGEMENT LP ($22,513,000 of principal), JPMORGAN CHASE & CO ($18,522,000 of principal), Invesco Ltd. ($14,627,000 of principal), AVIVA PLC ($12,300,000 of principal), Verition Fund Management LLC ($11,741,000 of principal), and Calamos Advisors LLC ($10,000,000 of principal).
This table shows the top 45 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.